BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
Industry: Healthcare

OFF LIST - 2677 consecutive market days: OFF LIST as of 10/17/2005 Through 11/14/2016

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.

Current Quote*
Last: $4.900
Change: 0.020
Book: $11.857
Volume: 291,929

As Of: 03/19 13:30 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol BDSI

Graphs for BDSI


3 Month Graph


6 Month Graph


1 Year Graph